take get board vertex train
vertex continu build leadership cf point
compani mani shot goal tripl program move
hetmin homozyg
combin hetmin novel corrector
continu show robust fev on-top teza/iva homozyg
popul see profound addit efficaci top teza/iva
popul relat quarter symdeko launch
solid start sale came demand
updat product forecast quarter new estim cf
busi new cf estim unchang previou
ep vs previou estim
fda view deuter kalydeco product new chemic
entiti wonder mean earlier competitor
compani disclos releas need dose work
character surpris fda view deuter
kalydeco new chemic entiti worri sinc
nice must wonder
conserv stanc relat fda mean potenti fast-follow
competitor look develop triplet regimen novel chemic
entiti think seen look robust
would increas conveni patient daili regimen view
delay think combin look interest
ep
previous risk outperform rate tp includ lower
expect cf sale clinic regulatori delay on-going tripl
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
vertex biotechnolog compani research develop
commerci small molecul drug focu cystic
fibrosi product kalydeco orkambi
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
cash-flow financ activ
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
blue sky scenario use dcf valu
share cut sg respect
grey sky scenario model less credit triplet
lower probabl success reflect increas risk
compani face meaning setback
 close
believ vertex uniqu posit clinic develop think
strong capabl mean reliant
build pipelin clear us compani remain opportunist
busi develop side fire power cash gener strength
cf revenu convers investor mani us includ believ
vertex could parti avx bid think deal
would great fit also want compani care
cash well
best biotech growth top bottom line next year think
good visibl growth well next year model
top bottom-lin growth assum peak cf revenu
assum take roughli market major mutat like
hetmin homozyg combin vertex capabl intern discov
asset think compani well posit next month
shift pipelin narr beyond cf key risk thesi remain
competit remain focus triplet develop
thesi think still upsid cf
valuat mostli play next engin
get mani question client around thesi comment
cystic fibrosi mostli price think anoth
tripl program confirm data come market could
upsid price triplet sinc efficaci significantli better current
therapi exampl highlight sensit charg vs base case
add dcf like learn price
rel peer also think compani intern
capabl help replenish pipelin new asset keep
eye pain program finish third vertex also move
anoth program clinic well also still capac
abil opportunist acquir licens interest extern asset
compani mention price
